+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality



Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality



Clinical Infectious Diseases 64(6): 711-718



Polymyxins including colistin are an important "last-line" treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKp). Increasing use of colistin has led to resistance to this cationic antimicrobial peptide. A cohort nested within the Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) was constructed of patients with infection, or colonization with CRKp isolates tested for colistin susceptibility during the study period of December, 2011 to October, 2014. Reference colistin resistance determination as performed by broth macrodilution was compared to results from clinical microbiology laboratories (Etest) and to polymyxin resistance testing. Each patient was included once, at the time of their first colistin-tested CRKp positive culture. Time to 30-day in-hospital all-cause mortality was evaluated by Kaplan-Meier curves and Cox proportional hazard modeling. In 246 patients with CRKp, 13% possessed ColR CRKp. ColR was underestimated by Etest (very major error rate = 35%, major error rate = 0.4%). A variety of rep-PCR strain types were encountered in both the ColS and the ColR groups. Carbapenem resistance was mediated primarily by blaKPC-2 (46%) and blaKPC-3 (50%). ColR was associated with increased hazard for in-hospital mortality (aHR 3.48; 95% confidence interval, 1.73-6.57; P < .001). The plasmid-associated ColR genes, mcr-1 and mcr-2 were not detected in any of the ColR CRKp. In this cohort, 13% of patients with CRKp presented with ColR CRKp. The apparent polyclonal nature of the isolates suggests de novo emergence of ColR in this cohort as the primary factor driving ColR. Importantly, mortality was increased in patients with ColR isolates.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057438246

Download citation: RISBibTeXText

PMID: 27940944

DOI: 10.1093/cid/ciw805


Related references

High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clinical Microbiology and Infection 19(1): E23-E30, 2013

Risk factors for the acquisition of colistin and carbapenem-resistant Klebsiella pneumoniae in Medelln-Colombia, an endemic region for carbapenem resistance. International Journal of Infectious Diseases 53: 39-40, 2016

Retraction. Characterization of carbapenem resistance mechanisms and in vitro synergistic activity of colistin plus meropenem in carbapenem resistant Klebsiella pneumoniae. Microbiology and Immunology 59(3): 182-182, 2016

Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: De Novo or Drug Exposure?. Clinical Infectious Diseases 65(4): 702-703, 2017

The threat of colistin resistance among carbapenem-resistant Klebsiella pneumoniae isolates in Iran. Iranian Journal of Microbiology 10(2): 72-73, 2018

Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae Mediated by Chromosomal Integration of Plasmid DNA. Antimicrobial Agents and ChemoTherapy 61(8), 2017

Carbapenem-Resistant Klebsiella pneumoniae: Results of a Laboratory Surveillance Program in an Italian General Hospital (August 2014-January 2015) : Surveillance of Carbapenem-resistant Klebsiella pneumoniae. Advances in Experimental Medicine and Biology 901: 91-101, 2017

Evaluation of ComASP™ Colistin (formerly SensiTest™ Colistin), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant Klebsiella pneumoniae isolates. Journal of Global Antimicrobial Resistance 15: 123-126, 2018

Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. Antimicrobial Agents and ChemoTherapy 61(8), 2017

Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). Journal of Infection 74(1): 103-106, 2016

Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance. Journal of ChemoTherapy 28(4): 297-303, 2017

Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveillance 19(42), 2015

Insertion sequence transpositions and point mutations in mgrB causing colistin resistance in a clinical strain of carbapenem-resistant Klebsiella pneumoniae from Vietnam. International Journal of Antimicrobial Agents 51(5): 789-793, 2017

Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance. Journal of ChemoTherapy 2015: 1973947815y0000000079, 2015

Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. Journal of Antimicrobial ChemoTherapy 70(3): 905-913, 2015